🏆 Deal of the Week · CW 28/2024
SciRhom raised EUR 63 million in a Series A round; the company's valuation was not disclosed. The round was backed by a syndicate of eight investors spanning Germany, France, Norway, and the United States. The financing will support advancement of SciRhom's lead iRhom2-targeting antibody program into clinical development.
SciRhom — key deal facts
| Company | SciRhom |
| Founded | 2016 |
| Headquarters | Martinsried, Germany |
| Amount raised | EUR 63M |
| Valuation | Valuation Remains Undisclosed |
| Round | Series A |
| Investors | Wellington Partners, PhiFund Ventures, MIG Capital, Kurma Partners, High-Tech Gruenderfonds, Hadean Ventures, Bayern Kapital, Andera Partners |
| Sectors | Biotechnology |
Who invested in SciRhom?
The round drew participation from Wellington Partners, PhiFund Ventures, MIG Capital, Kurma Partners, High-Tech Gruenderfonds, Hadean Ventures, Bayern Kapital, and Andera Partners. The investor mix is notable for combining early-stage German deep-tech specialists — High-Tech Gruenderfonds and Bayern Kapital — with dedicated life-science growth funds from France, Norway, and the US, reflecting broad cross-border conviction in the iRhom2 mechanism. The presence of multiple institutional biotech investors alongside public-sector-backed funds is consistent with the high capital requirements of first-in-class antibody programs.
What does SciRhom do?
SciRhom GmbH, founded in 2016 and headquartered at the Innovation and Startup Center (IZB) in Martinsried, Germany, is a clinical-stage biotechnology company developing first-in-class monoclonal antibodies that target iRhom2. Its lead candidate, SRS-878, is designed to simultaneously block multiple pro-inflammatory signaling pathways — including TNF-alpha and IL-6 — while preserving protective enzyme functions. The company targets autoimmune indications including rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis. SciRhom was co-founded by Prof. Dr. Carl Blobel, biotech investor Andreas Jenne, and Dr. Jens Ruhe, and is currently led by CEO Dr. Jan Poth.
SciRhom valuation & multiples
Explore the benchmarks: Series A.
Frequently asked questions
How much did SciRhom raise in its Series A?
SciRhom raised EUR 63 million in its Series A round, announced in 2024 (KW 28/2024).
What is SciRhom's valuation?
SciRhom's valuation was not disclosed in connection with this Series A financing.
Who invested in SciRhom?
The Series A was backed by Wellington Partners, PhiFund Ventures, MIG Capital, Kurma Partners, High-Tech Gruenderfonds, Hadean Ventures, Bayern Kapital, and Andera Partners.
When was SciRhom founded and where is it based?
SciRhom was founded in 2016 and is headquartered in Martinsried, Germany.
Source: original announcement — read the full report.